Worth reading
71In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
385
¥ millions (approximate amount of assets succeeded to)Wording
Definitive
How definitive the wording is.Decision and Details
Post-completion disclosure document relating to an incorporation-type company split
Decision8 October 2025 (date the incorporation-type company split plan was prepared)
Implementation1 April 2026 (effective date; completed)
AmountAmount of assets succeeded to (approximate): ¥385 million; amount of liabilities succeeded to (approximate): ¥267 million
Reason
To have the rights and obligations held in relation to the drug discovery business succeeded to by the newly established NANO MRNA Co., Ltd. This document sets out the disclosure items required under the Companies Act and the Ordinance for Enforcement of the Companies Act as a statutory post-event disclosure.
| Item | Details |
|---|---|
| Matter Covered | Post-completion disclosure document relating to an incorporation-type company split |
| Decision Date | 8 October 2025 (date the incorporation-type company split plan was prepared) |
| Implementation Date | 1 April 2026 (effective date; completed) |
| Amount | Amount of assets succeeded to (approximate): ¥385 million; amount of liabilities succeeded to (approximate): ¥267 million |
| Reason | To have the rights and obligations held in relation to the drug discovery business succeeded to by the newly established NANO MRNA Co., Ltd. This document sets out the disclosure items required under the Companies Act and the Ordinance for Enforcement of the Companies Act as a statutory post-event disclosure. |
| Governing Rule | Article 811, Paragraph 1, Item 1 and Article 805 of the Companies Act; Article 209 of the Ordinance for Enforcement of the Companies Act |
| Related previous disclosures | Incorporation-type company split plan prepared on 8 October 2025 |
Items this document does not state (5)
Decision-Making BodyPeriod CoveredQuantity / scaleImpact on Business PerformanceFuture plans
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is a statutory post-event disclosure made pursuant to Article 811, Paragraph 1, Item 1 of the Companies Act and Article 209 of the Ordinance for Enforcement of the Companies Act.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.